Market need Target hospitals and cardiology centers specializing in advanced heart failure to leverage CorWave’s wave membrane LVAD as a potential alternative to traditional LVADs, focusing on centers seeking devices with fewer complications and more physiologic flow.

Expansion leverage Capitalize on CorWave’s recent facility expansion and ramp-up of production by offering supply chain and manufacturing services, equipment vendors, and contract manufacturers to support scalable production and on-time deployment.

Clinical evidence Highlight opportunities to collaborate on clinical studies and real-world evidence demonstrations using the first-in-human implant results and HFSA-presented data to drive adoption and payer reimbursement discussions.

Strategic partnerships Position with global investors and specialized life sciences funds in CorWave’s network to unlock co-development, seed collaborations, and potential co-marketing arrangements with established LVAD players or distribution partners.

Operational readiness Offer turnkey operations support, including regulatory affairs, quality systems, and scale-up manufacturing expertise, to accelerate time-to-market and ensure compliant, reliable production for new implantable devices.